Recent Quotes (30 days)

You have no recent quotes
chg | %

Galapagos NV (ADR)  

(Public, NASDAQ:GLPG)   Watch this stock  
Find more results for GLPG
109.75
-1.11 (-1.00%)
Jan 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 109.45 - 110.84
52 week 63.69 - 113.04
Open 110.20
Vol / Avg. 0.00/100,370.00
Mkt cap 5.65B
P/E     -
Div/yield     -
EPS     -
Shares 50.94M
Beta 0.75
Inst. own     -
Feb 23, 2018
Q4 2017 Galapagos NV Earnings Call - 8:00AM EST - Add to calendar
Feb 22, 2018
Q4 2017 Galapagos NV Earnings Release - 4:00PM EST - Add to calendar
Jan 8, 2018
Galapagos NV at JPMorgan Healthcare Conference
Dec 6, 2017
Galapagos NV at Citi Global Healthcare Conference
Nov 17, 2017
Galapagos NV at Degroof Petercam Benelux Conference
Nov 17, 2017
Galapagos NV at Bryan Garnier Healthcare Conference
Nov 15, 2017
Galapagos NV at Stifel Healthcare Conference
Nov 15, 2017
Galapagos NV at Jefferies Global Healthcare Conference
Nov 6, 2017
Galapagos NV at Credit Suisse Healthcare Conference
Nov 6, 2017
Galapagos NV at EBD Group BioEurope Conference
More events from DailyFinance »    

Address

Generaal De Wittelaan 3
MALINES (MECHELEN), 2800
Belgium
+32-15-342900 (Phone)
+32-15-342901 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Officers and directors

Onno van de Stolpe Chief Executive Officer, Executive Director, Member of the Executive Committee
Age: 58
Bio & Compensation  - Reuters
Bart Filius Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer
Bio & Compensation  - Reuters
Piet Wigerinck Member of the Executive Committee, Chief Scientific Officer
Bio & Compensation  - Reuters
Elizabeth Goodwin VP Corporate Communications & Investor Relations
Bio & Compensation  - Reuters
Walid Abi-Saab Member of the Executive Committee, Chief Medical Officer
Bio & Compensation  - Reuters
Andre Hoekema Member of the Executive Committee, Chief Business Officer
Bio & Compensation  - Reuters
Rajesh Parekh Non-Executive Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Harrold van Barlingen Non-Executive Director
Age: 52
Bio & Compensation  - Reuters
Katrine Bosley Independent Non-Executive Director
Bio & Compensation  - Reuters
Werner Cautreels Non-Executive Independent Director
Age: 65
Bio & Compensation  - Reuters